New drug MT-7117 tested in healthy volunteers – no cure, just safety data
NCT ID NCT06994286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety and how the body processes the drug MT-7117 (dersimelagon) in 40 healthy Chinese adults aged 18 to 55. Participants received either the drug or a placebo, and researchers measured drug levels in the blood and monitored for side effects. The study is complete and does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MT-7117 (dersimelagon)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children